Why powder flow causes pharma scale-up failures
5 minute read
A blend that behaved well at 1 kg scale can fail at 100 kg. Understanding why – and measuring the right properties – is the foundation of successful pharmaceutical powder process development.
The scale-up paradox in pharmaceutical powder processing
Pharmaceutical powder scale-up failures follow a recognisable pattern. The blend performs well in development. The Carr's Index is acceptable. The angle of repose is within the target range. The small-scale tablet press produces consistent weight and hardness. Then at pilot scale, weight variation increases. At production scale, the tablet press requires constant manual adjustment. Occasionally the process is abandoned entirely, and reformulation begins.
Post-mortem analysis typically reveals that the laboratory characterisation was performed at a single condition - slow speed, small vessel, ambient humidity, freshly prepared powder - that did not represent the conditions encountered during large-scale production. The blend was not poorly characterised; it was characterised at the wrong conditions.
|
The fundamental issue Static flowability tests measure a powder once, at one condition, before any production stress has been applied. They cannot predict what happens at higher die fill speeds, under the head load of a full hopper, after humidity fluctuations in the compression suite, or during the extended production runs of a commercial batch. |
Variable 1: Die fill speed sensitivity
In tablet and capsule manufacturing, the speed at which blend fills the die or capsule body is a direct function of machine throughput. As production speed increases to meet demand, fill speed increases. If the blend's flow resistance changes with speed - and many do - tablet weight variation increases with throughput.
The PFA PFSD test characterises this directly, measuring resistance at five speeds and producing a Speed Sensitivity Ratio that predicts whether fill weight will remain consistent as machine speed changes. A blend with an SSR close to 1.0 is robust to speed changes; one with SSR significantly above 1.0 will produce declining tablet weight as throughput increases; one with SSR below 1.0 may flood at high speed, producing over-filled tablets.
This information, generated in a 15-minute laboratory test, allows process development teams to set validated speed limits before scale-up - not after the commercial batch has failed.
Variable 2: Compressibility and elastic recovery affecting tablet weight uniformity
In die filling, the powder column in the feed frame sits under the pressure of the material above it. If the blend is compressible - if it packs readily under applied load - the bulk density in the die varies with the fill level in the hopper. Early in a campaign, the full hopper exerts high head load, and the blend is dense. As the hopper empties, head load decreases and the blend is looser. Tablet weight drifts systematically across a batch without any change to the press settings.
PFA compressibility testing characterises this directly. The % Compressibility parameter measures how much the blend densifies under increasing normal stress. The Elastic Recovery parameter measures how much of that densification is permanent - a blend with low elastic recovery will not recover its original packing state as head load decreases, making the problem worse. Together these parameters identify blends susceptible to head-load-driven weight variation before the press is even started.
Variable 3: Cohesion and bridging - capping, sticking, and hopper discharge
Tablet capping - the separation of the tablet crown from the body after compression - has several causes, but one of the most common is poor blend cohesion at the particle level. A blend with high inter-particle cohesion may not delaminate properly during ejection, resulting in laminated or capped tablets. Conversely, a blend with a high Bridging Factor forms stable structural arches in the feed hopper, causing intermittent starving of the die - which manifests as erratic weight variation that is difficult to attribute to a single cause.
The PFA Cohesion test distinguishes these two failure modes directly. High Cohesion Index identifies blends with strong inter-particle bonding - relevant to capping and sticking risk. High Bridging Factor at low CI identifies blends prone to structural arching - relevant to hopper discharge reliability and feed frame consistency. These are different problems requiring different interventions, and a single flowability index cannot separate them.
Variable 4: Excipient variability between suppliers and grades
Pharmaceutical excipients are typically specified by grade, with limits on particle size, loss on drying, and in some cases Carr's Index or angle of repose. Within these limits, however, substantial variation in dynamic flow behaviour is possible - and that variation can be the difference between a blend that processes reliably and one that requires constant intervention.
Dynamic powder flow testing provides a sensitive, reproducible basis for excipient qualification that goes beyond attribute testing. A baseline fingerprint - cohesion, PFSD, compressibility, and conditioned bulk density - run consistently on each incoming batch detects the differences that matter in production. It also provides objective data for change control assessments when a supplier proposes a manufacturing process change that they assess as having no impact on performance.
|
ICH Q8 and process understanding Dynamic powder flow characterisation aligns with the ICH Q8 principle of understanding the design space for pharmaceutical processes. Speed Sensitivity Ratio and Flow Stability provide quantitative evidence of the throughput range over which a process will perform consistently - exactly the kind of process knowledge that supports design space definition. |
